Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic

University of Chile

Overview

Biofreeze® is a topical ointment that has menthol and alcamphor. Its analgesic effect lies in the stimulation of A and C fibers by cold and nociceptive stimulation, respectively, which is produced by menthol, apparently through the newly discovered receptor TRPM8 (Transient Receptor Potential melastatin-8) The aim of this study is to investigate if BIOFREEZE ® treatment (Performance Health Inc., Export, PA) improves symptoms associated with moderate knee osteoarthritis, which would decrease the immobility and isolation in older adults.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Conditions

Knee Osteoarthritis

Interventions

BiofreezeDRUG

Use of Biofreeze ointment

PlaceboOTHER

Use of placebo ointment

Eligibility

Sex: ALLMin age: 60 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Moderate osteoarthritis of the knee * Age 60 to 80 years * Ambulatory Exclusion Criteria: * Other conditions that affect mobility * Severe chronic diseases such as cardiac or renal failure * Cancer * Presence of gout * Cognitive impairment

Locations (1)

Institute of Nutrition and Food Technology

Santiago, Met, Chile

Outcomes

Primary Outcomes

WOMAC score

WOMAC score corresponds to Western Ontario and McMaster Universities Index of Osteoarthritis

Time frame: 60 days

Secondary Outcomes

Quality of life measured using SF 36

SF 36 correponds to a health related quality of life score

Time frame: 60 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.